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Introduction
Septic shock remains one of the leading causes of death in patients with infection. Individuals surviving the severe hypotension and respiratory failure typical of the acute phase of septic shock frequently progress to failure of multiple other organ systems. Appropriate treatment with antibiotics and supportive therapy is often unsuccessful at forestalling these events.
Therapies that might interfere at an early stage to prevent the development of such complications have not been forthcoming. One class of drugs, the glucocorticoids, showed initial promise. In animal models of septic shock using bacterial endotoxin (lipopolysaccharide, LPS) for the induction of shock, glucocorticoids were shown to protect against a lethal dose of LPS (1) (2) (3) . Early clinical trials also seemed to support the use of glucocorticoids in septic shock (4) . The issue has remained controversial however, and more recent studies concur that glucocorticoids do not improve the rate of survival in these patients (5, 6) .
A preliminary report ofthis work has appeared in abstract form (1988. Recent studies in our laboratory of the mechanisms of cachexia have led to the identification and purification of cachectin, a monokine produced in response to LPS (for review, see references 7 and 8) . Sequencing of the purified protein showed cachectin to be identical to tumor necrosis factor (TNF),' previously purified by other groups for its antitumor activity (9, 10) . Infusion of recombinant human cachectin/ TNF into rats causes a syndrome resembling septic shock, both in pathophysiology and histopathology (1 1). Furthermore, passive immunization against cachectin/TNF increases the survival rate of mice injected with a lethal dose of LPS ( 12) and protects baboons injected with live Escherichia coli (13) . These studies implicate cachectin/TNF as an essential endogenous mediator of gram-negative bacteremic shock.
Since glucocorticoids had been shown to protect against endotoxic shock in animal models, their effect on cachectin/ TNF production was examined. Kawakami et al. (14) showed that dexamethasone almost completely inhibits cachectin/ TNF production as measured by bioactivity. Beutler et al. (15) further examined this inhibition by looking at the cachectin/ TNF mRNA and protein levels in LPS-induced peritoneal macrophages (M4). It was found that the rate of transcription of cachectin/TNF mRNA decreases in the presence of dexamethasone, resulting in a partial suppression of cachectin/ TNF mRNA synthesis. However, there is simultaneously an almost complete suppression of the level of secreted cachectin/TNF, implicating a posttranscriptional site of action for dexamethasone. Thus, dexamethasone appears to inhibit cachectin/TNF production both transcriptionally and posttranscriptionally.
Given that dexamethasone so strongly inhibits cachectin/ TNF production by isolated macrophages, it is perhaps surprising that glucocorticoids have not been more successful at preventing septic shock in the clinical setting. The discrepancy between the effects of glucocorticoids in animal models and clinical trials suggests that the models do not (18) (19) (20) , is produced and secreted by T lymphocytes and large granular lymphocytes in response to antigens and T cell mitogens (reviewed in reference 21). It stimulates macrophages to increase their antimicrobial activity and the secretion of various inflammatory mediators and bactericidal agents (19, 22) . IFNy enhances cachectin/TNF production by human blood monocytes and murine peritoneal macrophages (23, 24). In addition, this lymphokine is able to override the genetic defect of endotoxin-resistant strains of mice (Ipsd phenotype), resulting in a significant increase in cachectin/TNF secretion by their macrophages when stimulated with LPS (25) .
In the present study, we investigated the combined effects of IFN'y and glucocorticoids on macrophage production of cachectin/TNF. We found that treatment with IFNy enabled macrophages to overcome dexamethasone-induced suppression of LPS-stimulated cachectin/TNF production. Hybridization ofRNA blots. An antisense RNA probe for cachectin/TNF mRNA was synthesized with the Gemini Riboprobe system from Promega Biotec, Madison, WI, using the method recommended by the manufacturer. RNA blots were hybridized overnight at 550C with the probe at 2 X I05 cpm/ml and washed in 0.1% SDS/0. I x SSC at 650C as described (27) . The filters were exposed to XAR-5 film (Eastman Kodak Co., Rochester, NY). Films were quantitated by scanning with a densitometer (Helena Laboratories, Beaumont, TX).
Methods
Western immunoblot. Macrophage-conditioned medium was adjusted to 6.5% trichloroacetic acid and 150 Ag/ml Micrococcus lysodeikticus (Sigma Chemical Co.), incubated on ice, and centrifuged for 10 min at 10,000 g. 
Results
Effect of IFNy on dexamethasone suppression of cachectin/ TNF production. The ability of murine peritoneal macrophages to produce cachectin/TNF in response to LPS was examined after pretreatment of the macrophages with either dexamethasone, IFN'y, or both agents. The macrophages were incubated for 1 h with dexamethasone and/or IFNy before the addition of LPS. The cells continued incubating with both LPS and the pretreatment reagents for 16 h more. The medium was collected and analyzed by Western immunoblot. As has been previously described, mature secreted murine cachectin/TNF is composed of multiple forms (30) . The major protein runs at 17 kD on SDS-PAGE (see Fig. 1 IFNzy has been shown to exhibit cytotoxic activity toward some cell lines independent of cachectin/TNF activity (31) . To affirm that the increased cytotoxicity measured in the bioassay was entirely due to increased cachectin/TNF production and not to a synergistic cytotoxic action of IFN-y transferred with the medium, the effect of IFNy on the cytotoxicity assay was tested (Fig. 3) . IFNy was added directly to the L-929 monolayer at the same time as conditioned medium from LPS-stimulated macrophages. At concentrations greater than or equaling that in the medium of macrophages that had been treated with IFNy, the lymphokine did not increase the cytotoxicity of Additions to macrophages Figure 2 . IFN-y antagonizes glucocorticoid suppression of cachectin/ TNF production. Peritoneal macrophages were incubated for I h with medium, 100 nM dexamethasone, or dexamethasone plus 1 U/ml IFNy, as indicated, before the addition of LPS to a final concentration of 100 ng/ml. 16 h after LPS addition, the medium was collected and preabsorbed with anti-cachectin/TNF antiserum or with normal rabbit serum. Aliquots were assayed for cytotoxic activity in the TNF bioassay. The data in cytotoxic units were reexpressed as the percentage of the cytotoxicity in the medium from cells treated with LPS alone. The results of multiple assays have been compiled. Error bars represent the SEM.
cachectin/TNF-containing medium. Thus, the IFNy-mediated enhancement of cachectin/TNF bioactivity, as measured by the L-929 cell assay, was not a result of direct action of IFN-y on the L-929 cells, but could be attributed to an effect on the macrophages to increase cachectin/TNF production.
IFN~y modulation ofLPS-induced cachectin/TNF production. The range of IFN'y concentrations effective at overcoming dexamethasone suppression was examined next. Macrophages were treated with dexamethasone, LPS, and various concentrations of IFNy, and 16 h later, the medium was tested for cytotoxic activity. As shown in Fig. 4 , as little as 0.1 U/ml IFN'y caused a significant increase in cachectin/TNF levels over those reached in the absence of IFN'y. The a maximum at 1 U/ml IFN'y. No further reversal ofdexamethasone suppression was achieved by increasing the concentration to 100 U/ml IFNy. When macrophages were treated with IFNy, in the absence of LPS and dexamethasone, no cytotoxic activity was detected (Fig. 4) . This was true throughout the range of IFNy concentrations tested, from 0.01 to 100 U/ml. In other experiments, 1,000 U/ml IFNy was also unable to stimulate cachectin/TNF production in the absence of LPS (data not shown). Thus, IFNy by itselfwas not able to induce cachectin/TNF synthesis.
Since IFNy is known to increase the sensitivity of macrophages to LPS, a concentration course of LPS was performed. Macrophages were treated with medium, dexamethasone, IFN'y, or both reagents, before the addition of various concentrations of LPS. The resultant cytotoxic activity in medium showed a dose-dependent increase in response to LPS (Fig. 5) with medium, 100 nM dexamethasone, 1 U/ml IFN-y, or both reagents. LPS was then added to achieve the indicated final concentrations, and the cells were incubated for an additional 16 h before collection of the medium for measurement ofcytotoxic activity. Results are expressed as cytotoxic units±SEM. thesis at two different levels (15) . They cause a decrease in the steady-state level of cachectin/TNF mRNA, and in addition, they appear to inhibit a later posttranslational step in the production of mature cachectin/TNF (Luedke, C., D.-M. Jue, and A. Cerami, manuscript in preparation). To determine the level at which IFNy acts to overcome dexamethasone suppression, cachectin/TNF mRNA levels were quantitated. Fig. 7 shows a representative experiment to examine the combined effect of IFN'y and dexamethasone on cachectin/TNF mRNA levels.
Macrophages were treated with LPS and increasing concentrations of dexamethasone with or without IFNy. Cytosolic RNA was harvested, dot blotted, and probed with radiolabeled antisense cachectin mRNA (Fig. 7 A) . The results of densitometric scanning of the blot's autoradiograph are displayed in Fig. 7 B. Dexamethasone and IFNy each independently modulated the mRNA level. As has been previously described elsewhere, dexamethasone suppressed steady-state cachectin/TNF mRNA levels to one third ofthe LPS-induced level (15 IFNy caused a significant reversal of glucocorticoid suppression at a concentration of 0.1 U/ml with the maximal effect at 1 U/ml. These concentrations are comparable to those required for other effects of IFNy on both murine and human macrophages (19, 32 (35) . This suggests that at the serum levels measured in septic patients, IFNT could counteract the glucocorticoid suppression of cachectin/TNF production. Comparison of IFNy levels in experimental bacteremia in animals with those in human sepsis suggests that the clinical failure of glucocorticoids might be attributable to a difference in the degree of activation of the immune system. When the serum concentrations of various cytokines are measured in baboons, after the infusion of a lethal dose of live Escherichia coli, the animals achieve peak serum cachectin/TNF levels 90 min after the bacterial infusion (16) . IFNy is not detectable in the serum until 2 h after the infusion and does not peak until 8 h. Thus, IFNy is not present at detectable levels during the first 90 min after the challenge, the period during which the lethal dose of cachectin/TNF is being produced. The protocol used here is typical of most of the animal studies of gram-negative shock, in that a single lethal dose of LPS or bacteria is given, causing the rapid onset of septic shock. It may be concluded that, in these studies, no IFNy is present to counteract glucocorticoid suppression of cachectin/TNF production. Thus in the animal models, glucocorticoids can effectively decrease cachectin/TNF production and its subsequent lethal effects.
In contrast, elevated serum levels of IFNy are observed in septic patients. High serum levels are found even in the absence of shock, that is, before the achievement of lethal levels of cachectin/TNF (17) . It was shown in that study that the levels of cachectin/TNF and IFNy each correlated positively with the severity of the disease. Although it is difficult to differentiate cause and effect, this correlation implies that blood monocytes are exposed to high IFNy concentrations during the peak period of cachectin/TNF synthesis. Thus, IFN'Y is likely to be present before or at the time that glucocorticoid therapy is begun and can interfere with glucocorticoid suppression of cachectin/TNF production.
The ability of IFNy to overcome glucocorticoid suppression of cachectin/TNF production in peritoneal macrophages in vitro was observed when IFNy was added any time from 2 d before to the same time as the glucocorticoid. Furthermore, it has been shown by others that fresh peripheral blood monocytes tend to be even more responsive to IFNy than are macrophages. Exposure of these blood monocytes to IFNy for as little as 6 h may result in an activated state lasting as long as 5-7 d after the removal ofthe lymphokine (35, 36) . Thus, even if the IFNy levels were elevated several hours before the administration of glucocorticoids, efficient glucocorticoid-induced suppression of cachectin/TNF production might not be possible.
Based on these various lines of evidence, combining the results of in vitro studies of murine peritoneal macrophages with in vitro and clinical observations of the human system, we postulate that the presence of IFNy in the serum of septic patients prevents efficient glucocorticoid suppression of cachectin/TNF production. The chronicity of clinical sepsis, unlike the animal models, allows for the presence ofIFNy during the early period of cachectin/TNF synthesis, thereby possibly affecting both the production and effects of this monokine. Since IFNy interferes with the suppressive action of glucocorticoids, this may partially explain the failure ofglucocorticoids to prevent the development of shock in clinical trials.
